This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Radiation therapy can cause significant toxicity in patients. Lower doses help limit this damage, but can also decrease the treatment’s effectiveness. Dr. Olcina is exploring how we might address these toxicities without compromising the treatment itself. Radiotherapy works in part by stimulating an adaptive immune response against cancer, which benefits patients. But it may also activate an innate immune response through the complement pathway that can promote tissue-damaging inflammation. To determine how we might prevent this, she’s characterizing how different doses of radiation activate the complement pathway and how it affects other immune cells, with the goal of identifying ways that immunotherapy might be able to boost radiotherapy’s benefits while reducing its drawbacks.
Stanford University | Bladder Cancer, Colorectal Cancer, Esophageal Cancer | 2016 | Amato J. Giaccia, Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).